A Phase I, Open Label Single-Arm Two-part Study to Investigate Safety, Pharmacokinetics, and Preliminary Efficacy of Pan-RAF/MEK Glue NST-628 Oral Tablets in Subject With Solid Tumors Harboring Genetic Alterations in the MAPK Pathway and With Other Solid Tumors

Disease Sites:

Not Available

Staging:

Phase I

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Not Available

Principal Investigator(s):

Berlin, Jordan

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

05-27-2025

Trial Type:

Treatment

Protocol ID:

VICC-DTPHI23579

National Clinical Trial ID:

NCT06326411

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available